IGXT 0.20 IntelGenx Technologies Corp.
| Range: | 0.09-0.2 | Vol Avg: | 0 | Last Div: | 0 | Changes: | 0 |
| Beta: | 2.57 | Cap: | 0.03B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Jan 17 2007 | Empoloyees: | 48 | ||
| CUSIP: | 45822R101 | CIK: | 0001098880 | ISIN: | US45822R1014 | Country: | CA |
| CEO: | Mr. Tommy Kenny J.D., L.L.B., M.Sc. | Website: | https://www.intelgenx.com | ||||
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow